These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 38590315)
1. Mechanisms of ferroptosis in nonalcoholic fatty liver disease and therapeutic effects of traditional Chinese medicine: a review. Wang N; Que H; Luo Q; Zheng W; Li H; Wang Q; Gu J Front Med (Lausanne); 2024; 11():1356225. PubMed ID: 38590315 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis. Wu Q; Chen Z; Ding Y; Tang Y; Cheng Y Front Nutr; 2022; 9():1033129. PubMed ID: 36330148 [TBL] [Abstract][Full Text] [Related]
3. Lipid Peroxidation in Ferroptosis and Association with Nonalcoholic Fatty Liver Disease. Zhao S; Guo Y; Yin X Front Biosci (Landmark Ed); 2023 Dec; 28(12):332. PubMed ID: 38179745 [TBL] [Abstract][Full Text] [Related]
4. Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease. Sui Y; Geng X; Wang Z; Zhang J; Yang Y; Meng Z Metabolism; 2024 Aug; 157():155953. PubMed ID: 38885833 [TBL] [Abstract][Full Text] [Related]
5. Iron metabolism and ferroptosis in nonalcoholic fatty liver disease: what is our next step? Shen X; Yu Z; Wei C; Hu C; Chen J Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E767-E775. PubMed ID: 38506752 [TBL] [Abstract][Full Text] [Related]
6. Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Vetuschi A; Cappariello A; Onori P; Gaudio E; Latella G; Pompili S; Sferra R Eur J Histochem; 2022 Jun; 66(3):. PubMed ID: 35726536 [TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M Gene; 2020 Jun; 742():144549. PubMed ID: 32184169 [TBL] [Abstract][Full Text] [Related]
10. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994 [TBL] [Abstract][Full Text] [Related]
11. Exploring Ganweikang Tablet as a Candidate Drug for NAFLD Through Network Pharmacology Analysis and Experimental Validation. Ma C; Wang X; Zhang J; Zhao Y; Hua Y; Zhang C; Zheng G; Yang G; Guan J; Li H; Li M; Kang L; Xiang J; Fan G; Yang S Front Pharmacol; 2022; 13():893336. PubMed ID: 35774609 [TBL] [Abstract][Full Text] [Related]
12. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Lee C; Kim J; Jung Y Cells; 2019 Oct; 8(10):. PubMed ID: 31619023 [TBL] [Abstract][Full Text] [Related]
13. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181 [TBL] [Abstract][Full Text] [Related]
14. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Kage M; Aishima S; Kusano H; Yano H J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250 [TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
16. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
17. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185 [TBL] [Abstract][Full Text] [Related]
18. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pydyn N; Miękus K; Jura J; Kotlinowski J Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853 [TBL] [Abstract][Full Text] [Related]
19. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Roeb E Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Yi YS J Ginseng Res; 2024 Mar; 48(2):122-128. PubMed ID: 38465218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]